Truist Securities Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $17

Truist Securities analyst Danielle Brill initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $17.